A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia

CASE PRESENTATION: In this case, we share a case of one of our patients developed rhabdomyolysis after he was administered roxadustat to treat anaemia caused by chronic renal failure. DISCUSSION: More than 1.2 million people died from chronic kidney damage (CKD) globally, in 2017. Anaemia is a commo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qin, Wang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243928/
https://www.ncbi.nlm.nih.gov/pubmed/33411966
http://dx.doi.org/10.1111/ijcp.14011
Descripción
Sumario:CASE PRESENTATION: In this case, we share a case of one of our patients developed rhabdomyolysis after he was administered roxadustat to treat anaemia caused by chronic renal failure. DISCUSSION: More than 1.2 million people died from chronic kidney damage (CKD) globally, in 2017. Anaemia is a common complication of CKD. Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Roxadustat is often used to treat anaemia caused by renal failure. Its adverse effects include high blood pressure, myocardial infarction, heart failure, high potassium, and dizziness; however, there are no reports about rhabdomyolysis associated with roxadustat. CONCLUSION: Physicians should be alert about the occurrence of rhabdomyolysis when roxadustat is used.

Ejemplares similares